ReviewAntibiotics (Basel, Switzerland)2023
Bacteriophage-Antibiotic Combination Therapy against
Review in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Bacteriophage therapy for multidrug-resistant bacterial infections: recent advances, clinical evidence, and translational challenges.Archives of microbiology · 2026Review
- Inhaled Antibiotic and Biologic Formulations TargetingPharmaceutics · 2026Review
- A novel isolated phage targeting Pseudomonas aeruginosa demonstrates therapeutic potential.PloS one · 2026Article
- Characterisation of a NovelPathogens (Basel, Switzerland) · 2025Article
- Understanding phage Receptor-binding protein interaction with host surface receptor: the key for phage-Mediated detection and elimination of Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Multidrug-resistantVirulence · 2025Review
- Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.Pharmaceutics · 2025Review
- The virulent bacteriophage Henu8 as an antimicrobial synergist againstMicrobiology spectrum · 2025Article
- Phage Therapy in Managing Multidrug-Resistant (MDR) Infections in Cancer Therapy: Innovations, Complications, and Future Directions.Pharmaceutics · 2025Review
- Complete genome sequences of threeMicrobiology resource announcements · 2025Article
- In Vitro Interactions Between Bacteriophages and Antibacterial Agents of Various Classes Against Multidrug-Resistant Metallo-β-Lactamase-ProducingPharmaceuticals (Basel, Switzerland) · 2025Article
- Phage-antibiotic combinations againstFrontiers in microbiology · 2025Article
- Complete genome sequences of threeMicrobiology resource announcements · 2024Article
- Phage therapy as a glimmer of hope in the fight against the recurrence or emergence of surgical site bacterial infections.Infection · 2024Review
- Automating Predictive Phage Therapy Pharmacology.Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Phage therapy is an alternative therapy that is being used as the last resource against infections caused by multidrug-resistant bacteria after the failure of standard treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.